1/15
02:00 pm
bhvn
Biohaven CEO Dr. Vlad Coric goes one-on-one with Jim Cramer [CNBC]
Low
Report
Biohaven CEO Dr. Vlad Coric goes one-on-one with Jim Cramer [CNBC]
1/14
07:19 pm
bhvn
Biohaven CEO Dr. Vlad Corcic goes one-on-one with Jim Cramer [CNBC]
Medium
Report
Biohaven CEO Dr. Vlad Corcic goes one-on-one with Jim Cramer [CNBC]
1/12
12:37 pm
bhvn
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/12
12:07 pm
bhvn
Biohaven Provides Updates on Several Clinical Programs; Shares Rise [Yahoo! Finance]
Medium
Report
Biohaven Provides Updates on Several Clinical Programs; Shares Rise [Yahoo! Finance]
1/12
11:15 am
bhvn
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
1/7
07:40 am
bhvn
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 [Yahoo! Finance]
High
Report
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 [Yahoo! Finance]
1/7
07:00 am
bhvn
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
High
Report
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
1/6
10:37 am
bhvn
Biohaven (NYSE:BHVN) had its price target lowered by analysts at Morgan Stanley from $26.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
Biohaven (NYSE:BHVN) had its price target lowered by analysts at Morgan Stanley from $26.00 to $21.00. They now have an "overweight" rating on the stock.
1/5
03:24 am
bhvn
The Bull Case For Biohaven (BHVN) Could Change Following BHV-7000 MDD Trial Halt And R&D Pivot [Yahoo! Finance]
Medium
Report
The Bull Case For Biohaven (BHVN) Could Change Following BHV-7000 MDD Trial Halt And R&D Pivot [Yahoo! Finance]
12/26
09:26 am
bhvn
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise [Seeking Alpha]
High
Report
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise [Seeking Alpha]
12/26
07:40 am
bhvn
Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More Stock Market Movers [Barron's]
High
Report
Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More Stock Market Movers [Barron's]
12/26
07:34 am
bhvn
Biohaven defended despite depression trial setback [Seeking Alpha]
High
Report
Biohaven defended despite depression trial setback [Seeking Alpha]
12/26
07:17 am
bhvn
Biohaven (NYSE:BHVN) had its "market perform" rating reaffirmed by analysts at William Blair.
High
Report
Biohaven (NYSE:BHVN) had its "market perform" rating reaffirmed by analysts at William Blair.
12/26
07:17 am
bhvn
Biohaven (NYSE:BHVN) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Biohaven (NYSE:BHVN) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/26
07:17 am
bhvn
Biohaven (NYSE:BHVN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
High
Report
Biohaven (NYSE:BHVN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
12/24
04:29 pm
bhvn
Biohaven's depression drug fails mid-stage trial, shares fall [Yahoo! Finance]
High
Report
Biohaven's depression drug fails mid-stage trial, shares fall [Yahoo! Finance]
12/24
01:57 pm
bhvn
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder [Yahoo! Finance]
Neutral
Report
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder [Yahoo! Finance]
12/24
01:00 pm
bhvn
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
Neutral
Report
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
12/20
10:22 am
bhvn
Biohaven (BHVN): Valuation Check After Encouraging BHV-1510 Immuno-Oncology Data at ESMO Congress [Yahoo! Finance]
Low
Report
Biohaven (BHVN): Valuation Check After Encouraging BHV-1510 Immuno-Oncology Data at ESMO Congress [Yahoo! Finance]
12/20
04:46 am
bhvn
Biohaven (BHVN) Is Down 5.9% After New BHV-1510 Combo Data - What's Changed [Yahoo! Finance]
Low
Report
Biohaven (BHVN) Is Down 5.9% After New BHV-1510 Combo Data - What's Changed [Yahoo! Finance]
12/11
07:22 am
bhvn
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress [Yahoo! Finance]
Medium
Report
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress [Yahoo! Finance]
12/11
07:00 am
bhvn
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
Medium
Report
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
12/3
07:19 am
bhvn
Biohaven (NYSE:BHVN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
Low
Report
Biohaven (NYSE:BHVN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
11/29
02:38 pm
bhvn
Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost [Yahoo! Finance]
Medium
Report
Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost [Yahoo! Finance]
11/26
06:04 am
bhvn
Biohaven (NYSE:BHVN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
Low
Report
Biohaven (NYSE:BHVN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.